WORLDglobal
Indian firms are lining up to take advantage Novo patent expiry
Single source
Updated 3 hours ago
First seen March 20, 2026 20:40:38Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Novo Nordisk’s patent for semaglutide, the active ingredient in its weight-loss medication, expires in India this Friday. Consequently, 40 companies are expected to launch cheaper versions, which doctors predict could more than double the number of patients seeking treatment. This shift occurs as obesity rates rise, with 24 percent of women and 23 percent of […]